Reports
Reports
The pain management therapeutics market is poised for steady growth, owing to increasing prevalence of chronic pain conditions including arthritis, neuropathic pain, and pain related to cancer – particularly in aging population. North America has the most advanced market due to it being home to established healthcare delivery systems and significant chronic pain burden on the healthcare system.
.webp "Pain Management Therapeutics Market Revenue Growth (USD Bn)")
Meanwhile, emerging markets in Asia-Pacific, Latin America, and Africa have a great growth opportunity with improvement in access to healthcare and awareness regarding the same. Some of the key factors driving the growth of the market include, but are not limited to increasing incidence of chronic pain, development of drug delivery systems such as transdermal patches, sustained-release drug formulations, and that the geriatric population is growing causing the need for solutions for age-related chronic pain.
The market is not without restraints, including the existing opioid crisis resulting from strict regulatory requirements limiting the opioid-based therapies, potential side-effects of medications including adhesive/pain relief patches, non-steroidal anti-inflammatory drugs (NSAIDs) or gabapentinoids, and the cost of advanced treatments noting that in less-developed regions, neuromodulation and biologics have typically high costs that restrict the market.
Opportunities include understanding and exploring personalized medicine where a biomarker directs treatment course, growth of emerging markets when healthcare systems develop, increase in the utilization of new biologic treatments, anticonvulsants, and new technologies including wearable devices, nerve stimulation devices, and nanoparticle-based treatments as alternatives to opioids while also increasing innovation in the market on the whole.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The increasing incidences of chronic pain will be a significant contributor to the pain management therapeutics market. Frequency of chronic pain conditions such as arthritis, fibromyalgia, lower back, neuropathic pain and cancer pain is increasing all over the world. Many reasons are contributing to the rise of chronic pain, particularly aging of population, inactivity, and rising incidence of disease such as obesity and diabetes.
According to data published by Centers for Disease Control and Prevention in April 2023, during 2021, an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain (i.e., chronic pain that results in substantial restriction to daily activities) with a higher prevalence among non-Hispanic American Indian or Alaska Native adults. The increase in population suffering from chronic pain is stimulating additional demand for pharmacologic and non-pharmacologic samples of pain relief.
New approaches to drug formulation and delivery are likely to dramatically enhance the pain management therapeutics market due to improved efficacy, compliance, and safety. Innovations such as sustained-release formulations, transdermal patches, liposomal drug delivery, and targeted release drug delivery allow for more stable pain control, with less side-effects and low burden of dependency (the latter is particularly critical regarding opioids).
Also, innovations in non-opioid analgesics, especially combinations of drugs, are evolving to meet the need for safer options for long-term pain management. Most importantly, developments with injectable biologics, or gene therapy for conditions such as neuropathic and inflammatory pain are gaining momentum, allowing for personalized and longer-acting pain relief. These advances not only support the delivery of better patient outcomes, but also have the potential to increase revenue for pharmaceutical companies by differentiation to competitive drugs.
As more number of health practitioners, look for alternatives to oral opioids, delivery of pain medications through alternative methods has become a key strategic opportunity in the evolution of the modern pain management process and will be a significant contributor to growth in the pain management therapeutics market.
Opioids represent is dominating the pain management therapeutics market due to their established role in moderate to severe pain management. Opioids are the most widely utilized treatment for surgeries, cancer, injury, and chronic pain syndromes, including several debilitating conditions like arthritis and neuropathy. Opioids are the favored choice of healthcare providers due to the strong analgesia as compared to the other treatment options when they are ineffective.
While there is a growing concern and regulatory effort around addiction and misuse, opioids have become a mainstay of pain management protocols, especially for acute care. Improvements to formulations such as extended-release and abuse deterrent features have been developed to target safety concerns for more controlled or longer use of the medication.
Furthermore, the increase in surgical procedures and the rising chronic disease burden create demand for opioid-based therapies. As emerging markets have greater access to the latest advanced healthcare, opioid use is expected to widen and continue to reinforce the importance of opioids for longer-lasting pain management globally.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America is leading the pain management therapeutics market as a result of its sophisticated healthcare infrastructure, high incidence of chronic pain disorders, and high rates of implementation of new therapies. There is a sizable patient population with arthritis, cancer, back pain, or neuropathic disorders in North America, placing long-term pain management at a high priority level.
With considerable insurance coverage, good reimbursement policies, and access to specialists and hospitals, the United States allows for widespread use of pharmacological and non-pharmacological therapies to treat multiple chronic pain conditions. North America also houses many of the most comprehensive and advanced pharmaceutical and biotech organizations, with a focus on developing new pain medications and therapeutics including new non-opioid drugs and formulating new delivery systems.
R&D support, increasing awareness of all pain management therapies, and trends toward personalized, digital opportunities is only improving North America's position as the leader in the pain management therapeutics market. As highlighted in the report, opioid dependency has created obstacles for many organizations, but North America remains the leader in both - innovation and consumption in the pain therapeutics space.
Pfizer Inc., Eli Lilly and Company, GSK plc, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Abbott, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, AstraZeneca, Endo, Inc., Bayer AG, Sanofi, Viatris Inc., Haleon plc, Impax Laboratories, Inc., Lupin Limited, and other prominent players are operating in the global Market.
Each of these players has been profiled in the pain management therapeutics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 81.2 Bn |
| Forecast Value in 2035 | US$ 110.0 Bn |
| CAGR | 2.8% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 81.2 Bn in 2024.
It is projected to cross US$ 110.0 Bn by the end of 2035.
Rising prevalence of chronic pain conditions, innovations in drug formulations and delivery methods and paradigm shift towards multimodal pain management.
It is anticipated to grow at a CAGR of 2.8% from 2025 to 2035.
North America is expected to account for the largest share from 2025 to 2035.
Pfizer Inc., Eli Lilly and Company, GSK plc, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Abbott, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, AstraZeneca, Endo, Inc., Bayer AG, Sanofi, Viatris Inc., Haleon plc, Impax Laboratories, Inc., Lupin Limited, and other prominent players.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Pain Management Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pain Management Therapeutics Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Regulatory Landscape across Key Regions/Countries
5.2. Market Trends
5.3. PORTER’s Five Forces Analysis
5.4. PESTEL Analysis
5.5. Key Purchase Metrics for End-users
5.6. Brand and Pricing Analysis
5.7. Pipeline Analysis
5.8. Epidemiology of Major Diseases
6. Global Pain Management Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Class, 2020 to 2035
6.3.1. Anticonvulsants
6.3.2. Antidepressants
6.3.3. Anaesthetics
6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.5. Opioids
6.3.6. Anti-migraine Agents
6.3.7. Other
6.4. Market Attractiveness By Drug Class
7. Global Pain Management Therapeutics Market Analysis and Forecasts, By Drug Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Drug Type, 2020 to 2035
7.3.1. Over-the-Counter (OTC) Drugs
7.3.2. Prescription Drugs
7.4. Market Attractiveness By Drug Type
8. Global Pain Management Therapeutics Market Analysis and Forecasts, By Pain Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Pain Type, 2020 to 2035
8.3.1. Acute Pain
8.3.2. Chronic Pain
8.4. Market Attractiveness By Pain Type
9. Global Pain Management Therapeutics Market Analysis and Forecasts, By Route of Administration
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Route of Administration, 2020 to 2035
9.3.1. Oral
9.3.2. Parenteral
9.3.3. Topical
9.3.4. Others
9.4. Market Attractiveness By Route of Administration
10. Global Pain Management Therapeutics Market Analysis and Forecasts, By Indication
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Indication, 2020 to 2035
10.3.1. Arthritic Pain
10.3.2. Bone Facture
10.3.3. Cancer Pain
10.3.4. Chronic Back Pain
10.3.5. Fibromyalgia
10.3.6. Migraine
10.3.7. Muscle Sprain/Strain
10.3.8. Neuropathic Pain
10.3.9. Post-Operative Pain
10.3.10. Others
10.4. Market Attractiveness By Indication
11. Global Pain Management Therapeutics Market Analysis and Forecasts, By Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast By Distribution Channel, 2020 to 2035
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness By Distribution Channel
12. Global Pain Management Therapeutics Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness By Region
13. North America Pain Management Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2020 to 2035
13.2.1. Anticonvulsants
13.2.2. Antidepressants
13.2.3. Anaesthetics
13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.2.5. Opioids
13.2.6. Anti-migraine Agents
13.2.7. Other
13.3. Market Value Forecast By Drug Type, 2020 to 2035
13.3.1. Over-the-Counter (OTC) Drugs
13.3.2. Prescription Drugs
13.4. Market Value Forecast By Pain Type, 2020 to 2035
13.4.1. Acute Pain
13.4.2. Chronic Pain
13.5. Market Value Forecast By Route of Administration, 2020 to 2035
13.5.1. Oral
13.5.2. Parenteral
13.5.3. Topical
13.5.4. Others
13.6. Market Value Forecast By Indication, 2020 to 2035
13.6.1. Arthritic Pain
13.6.2. Bone Facture
13.6.3. Cancer Pain
13.6.4. Chronic Back Pain
13.6.5. Fibromyalgia
13.6.6. Migraine
13.6.7. Muscle Sprain/Strain
13.6.8. Neuropathic Pain
13.6.9. Post-Operative Pain
13.6.10. Others
13.7. Market Value Forecast By Distribution Channel, 2020 to 2035
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast By Country, 2020 to 2035
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Drug Class
13.9.2. By Drug Type
13.9.3. By Pain Type
13.9.4. By Route of Administration
13.9.5. By Indication
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Pain Management Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2020 to 2035
14.2.1. Anticonvulsants
14.2.2. Antidepressants
14.2.3. Anaesthetics
14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.2.5. Opioids
14.2.6. Anti-migraine Agents
14.2.7. Other
14.3. Market Value Forecast By Drug Type, 2020 to 2035
14.3.1. Over-the-Counter (OTC) Drugs
14.3.2. Prescription Drugs
14.4. Market Value Forecast By Pain Type, 2020 to 2035
14.4.1. Acute Pain
14.4.2. Chronic Pain
14.5. Market Value Forecast By Route of Administration, 2020 to 2035
14.5.1. Oral
14.5.2. Parenteral
14.5.3. Topical
14.5.4. Others
14.6. Market Value Forecast By Indication, 2020 to 2035
14.6.1. Arthritic Pain
14.6.2. Bone Facture
14.6.3. Cancer Pain
14.6.4. Chronic Back Pain
14.6.5. Fibromyalgia
14.6.6. Migraine
14.6.7. Muscle Sprain/Strain
14.6.8. Neuropathic Pain
14.6.9. Post-Operative Pain
14.6.10. Others
14.7. Market Value Forecast By Distribution Channel, 2020 to 2035
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Italy
14.8.5. Spain
14.8.6. Switzerland
14.8.7. The Netherlands
14.8.8. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Drug Class
14.9.2. By Drug Type
14.9.3. By Pain Type
14.9.4. By Route of Administration
14.9.5. By Indication
14.9.6. By Distribution Channel
14.9.7. By Country/Sub-region
15. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Drug Class, 2020 to 2035
15.2.1. Anticonvulsants
15.2.2. Antidepressants
15.2.3. Anaesthetics
15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
15.2.5. Opioids
15.2.6. Anti-migraine Agents
15.2.7. Other
15.3. Market Value Forecast By Drug Type, 2020 to 2035
15.3.1. Over-the-Counter (OTC) Drugs
15.3.2. Prescription Drugs
15.4. Market Value Forecast By Pain Type, 2020 to 2035
15.4.1. Acute Pain
15.4.2. Chronic Pain
15.5. Market Value Forecast By Route of Administration, 2020 to 2035
15.5.1. Oral
15.5.2. Parenteral
15.5.3. Topical
15.5.4. Others
15.6. Market Value Forecast By Indication, 2020 to 2035
15.6.1. Arthritic Pain
15.6.2. Bone Facture
15.6.3. Cancer Pain
15.6.4. Chronic Back Pain
15.6.5. Fibromyalgia
15.6.6. Migraine
15.6.7. Muscle Sprain/Strain
15.6.8. Neuropathic Pain
15.6.9. Post-Operative Pain
15.6.10. Others
15.7. Market Value Forecast By Distribution Channel, 2020 to 2035
15.7.1. Hospital Pharmacies
15.7.2. Retail Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. South Korea
15.8.6. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Drug Class
15.9.2. By Drug Type
15.9.3. By Pain Type
15.9.4. By Route of Administration
15.9.5. By Indication
15.9.6. By Distribution Channel
15.9.7. By Country/Sub-region
16. Latin America Pain Management Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Drug Class, 2020 to 2035
16.2.1. Anticonvulsants
16.2.2. Antidepressants
16.2.3. Anaesthetics
16.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
16.2.5. Opioids
16.2.6. Anti-migraine Agents
16.2.7. Other
16.3. Market Value Forecast By Drug Type, 2020 to 2035
16.3.1. Over-the-Counter (OTC) Drugs
16.3.2. Prescription Drugs
16.4. Market Value Forecast By Pain Type, 2020 to 2035
16.4.1. Acute Pain
16.4.2. Chronic Pain
16.5. Market Value Forecast By Route of Administration, 2020 to 2035
16.5.1. Oral
16.5.2. Parenteral
16.5.3. Topical
16.5.4. Others
16.6. Market Value Forecast By Indication, 2020 to 2035
16.6.1. Arthritic Pain
16.6.2. Bone Facture
16.6.3. Cancer Pain
16.6.4. Chronic Back Pain
16.6.5. Fibromyalgia
16.6.6. Migraine
16.6.7. Muscle Sprain/Strain
16.6.8. Neuropathic Pain
16.6.9. Post-Operative Pain
16.6.10. Others
16.7. Market Value Forecast By Distribution Channel, 2020 to 2035
16.7.1. Hospital Pharmacies
16.7.2. Retail Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Argentina
16.8.4. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Drug Class
16.9.2. By Drug Type
16.9.3. By Pain Type
16.9.4. By Route of Administration
16.9.5. By Indication
16.9.6. By Distribution Channel
16.9.7. By Country/Sub-region
17. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast By Drug Class, 2020 to 2035
17.2.1. Anticonvulsants
17.2.2. Antidepressants
17.2.3. Anaesthetics
17.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
17.2.5. Opioids
17.2.6. Anti-migraine Agents
17.2.7. Other
17.3. Market Value Forecast By Drug Type, 2020 to 2035
17.3.1. Over-the-Counter (OTC) Drugs
17.3.2. Prescription Drugs
17.4. Market Value Forecast By Pain Type, 2020 to 2035
17.4.1. Acute Pain
17.4.2. Chronic Pain
17.5. Market Value Forecast By Route of Administration, 2020 to 2035
17.5.1. Oral
17.5.2. Parenteral
17.5.3. Topical
17.5.4. Others
17.6. Market Value Forecast By Indication, 2020 to 2035
17.6.1. Arthritic Pain
17.6.2. Bone Facture
17.6.3. Cancer Pain
17.6.4. Chronic Back Pain
17.6.5. Fibromyalgia
17.6.6. Migraine
17.6.7. Muscle Sprain/Strain
17.6.8. Neuropathic Pain
17.6.9. Post-Operative Pain
17.6.10. Others
17.7. Market Value Forecast By Distribution Channel, 2020 to 2035
17.7.1. Hospital Pharmacies
17.7.2. Retail Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Drug Class
17.9.2. By Drug Type
17.9.3. By Pain Type
17.9.4. By Route of Administration
17.9.5. By Indication
17.9.6. By Distribution Channel
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player – Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis By Company (2024)
18.3. Company Profiles
18.3.1. Pfizer Inc.
18.3.1.1. Company Overview
18.3.1.2. Financial Overview
18.3.1.3. Product Portfolio
18.3.1.4. Business Strategies
18.3.1.5. Recent Developments
18.3.2. Eli Lilly and Company
18.3.2.1. Company Overview
18.3.2.2. Financial Overview
18.3.2.3. Product Portfolio
18.3.2.4. Business Strategies
18.3.2.5. Recent Developments
18.3.3. GSK plc
18.3.3.1. Company Overview
18.3.3.2. Financial Overview
18.3.3.3. Product Portfolio
18.3.3.4. Business Strategies
18.3.3.5. Recent Developments
18.3.4. Merck & Co., Inc.
18.3.4.1. Company Overview
18.3.4.2. Financial Overview
18.3.4.3. Product Portfolio
18.3.4.4. Business Strategies
18.3.4.5. Recent Developments
18.3.5. Novartis AG
18.3.5.1. Company Overview
18.3.5.2. Financial Overview
18.3.5.3. Product Portfolio
18.3.5.4. Business Strategies
18.3.5.5. Recent Developments
18.3.6. Johnson & Johnson Services, Inc.
18.3.6.1. Company Overview
18.3.6.2. Financial Overview
18.3.6.3. Product Portfolio
18.3.6.4. Business Strategies
18.3.6.5. Recent Developments
18.3.7. Abbott
18.3.7.1. Company Overview
18.3.7.2. Financial Overview
18.3.7.3. Product Portfolio
18.3.7.4. Business Strategies
18.3.7.5. Recent Developments
18.3.8. Teva Pharmaceutical Industries Ltd.
18.3.8.1. Company Overview
18.3.8.2. Financial Overview
18.3.8.3. Product Portfolio
18.3.8.4. Business Strategies
18.3.8.5. Recent Developments
18.3.9. Mallinckrodt Pharmaceuticals
18.3.9.1. Company Overview
18.3.9.2. Financial Overview
18.3.9.3. Product Portfolio
18.3.9.4. Business Strategies
18.3.9.5. Recent Developments
18.3.10. AstraZeneca
18.3.10.1. Company Overview
18.3.10.2. Financial Overview
18.3.10.3. Product Portfolio
18.3.10.4. Business Strategies
18.3.10.5. Recent Developments
18.3.11. Endo, Inc.
18.3.11.1. Company Overview
18.3.11.2. Financial Overview
18.3.11.3. Product Portfolio
18.3.11.4. Business Strategies
18.3.11.5. Recent Developments
18.3.12. Bayer AG
18.3.12.1. Company Overview
18.3.12.2. Financial Overview
18.3.12.3. Product Portfolio
18.3.12.4. Business Strategies
18.3.12.5. Recent Developments
18.3.13. Sanofi
18.3.13.1. Company Overview
18.3.13.2. Financial Overview
18.3.13.3. Product Portfolio
18.3.13.4. Business Strategies
18.3.13.5. Recent Developments
18.3.14. Viatris Inc
18.3.14.1. Company Overview
18.3.14.2. Financial Overview
18.3.14.3. Product Portfolio
18.3.14.4. Business Strategies
18.3.14.5. Recent Developments
18.3.15. Haleon plc
18.3.15.1. Company Overview
18.3.15.2. Financial Overview
18.3.15.3. Product Portfolio
18.3.15.4. Business Strategies
18.3.15.5. Recent Developments
18.3.16. Impax Laboratories, Inc.
18.3.16.1. Company Overview
18.3.16.2. Financial Overview
18.3.16.3. Product Portfolio
18.3.16.4. Business Strategies
18.3.16.5. Recent Developments
18.3.17. Lupin Limited
18.3.17.1. Company Overview
18.3.17.2. Financial Overview
18.3.17.3. Product Portfolio
18.3.17.4. Business Strategies
18.3.17.5. Recent Developments
List of Tables
Table 01: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 02: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020 to 2035
Table 03: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Pain Type, 2020 to 2035
Table 04: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 05: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 06: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 07: Global Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 08: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 09: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 10: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020 to 2035
Table 11: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Pain Type, 2020 to 2035
Table 12: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 13: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 14: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 15: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 16: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 17: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020 to 2035
Table 18: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Pain Type, 2020 to 2035
Table 19: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 20: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 21: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 22: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 23: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 24: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020 to 2035
Table 25: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Pain Type, 2020 to 2035
Table 26: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 27: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 28: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 29: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 30: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 31: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020 to 2035
Table 32: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Pain Type, 2020 to 2035
Table 33: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 34: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 35: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 36: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 37: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 38: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020 to 2035
Table 39: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, by Pain Type, 2020 to 2035
Table 40: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 41: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 42: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
List of Figures
Figure 01: Global Pain Management Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 02: Global Pain Management Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 03: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Anticonvulsants, 2020 to 2035
Figure 04: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Antidepressants, 2020 to 2035
Figure 05: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Anaesthetics, 2020 to 2035
Figure 06: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2020 to 2035
Figure 07: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Opioids, 2020 to 2035
Figure 08: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Anti-migraine Agents, 2020 to 2035
Figure 09: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 10: Global Pain Management Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 11: Global Pain Management Therapeutics Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 12: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Over-the-Counter (OTC), 2020 to 2035
Figure 13: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Prescription Drugs, 2020 to 2035
Figure 14: Global Pain Management Therapeutics Market Value Share Analysis, By Pain Type, 2024 and 2035
Figure 15: Global Pain Management Therapeutics Market Attractiveness Analysis, By Pain Type, 2025 to 2035
Figure 16: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Acute Pain, 2020 to 2035
Figure 17: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Chronic Pain, 2020 to 2035
Figure 18: Global Pain Management Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 19: Global Pain Management Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 20: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Oral, 2020 to 2035
Figure 21: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Parenteral, 2020 to 2035
Figure 22: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Topical, 2020 to 2035
Figure 23: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 24: Global Pain Management Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
Figure 25: Global Pain Management Therapeutics Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 26: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Arthritic Pain, 2020 to 2035
Figure 27: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Bone Fracture, 2020 to 2035
Figure 28: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Cancer Pain, 2020 to 2035
Figure 29: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Chronic Back Pain, 2020 to 2035
Figure 30: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Fibromyalgia, 2020 to 2035
Figure 31: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Migraine, 2020 to 2035
Figure 32: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Muscle Sprain/Strain, 2020 to 2035
Figure 33: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Neuropathic Pain, 2020 to 2035
Figure 34: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Post-operative Pain, 2020 to 2035
Figure 35: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 36: Global Pain Management Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 37: Global Pain Management Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 38: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Hospital Pharmacies, 2020 to 2035
Figure 39: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Retail Pharmacies, 2020 to 2035
Figure 40: Global Pain Management Therapeutics Market Revenue (US$ Bn), by Online Pharmacies, 2020 to 2035
Figure 41: Global Pain Management Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
Figure 42: Global Pain Management Therapeutics Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 43: North America Pain Management Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 44: North America Pain Management Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
Figure 45: North America Pain Management Therapeutics Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 46: North America Pain Management Therapeutics Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 47: North America Pain Management Therapeutics Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 48: North America Pain Management Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 49: North America Pain Management Therapeutics Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 50: North America Pain Management Therapeutics Market Value Share Analysis, By Pain Type, 2024 and 2035
Figure 51: North America Pain Management Therapeutics Market Attractiveness Analysis, By Pain Type, 2025 to 2035
Figure 52: North America Pain Management Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 53: North America Pain Management Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 54: North America Pain Management Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
Figure 55: North America Pain Management Therapeutics Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 56: North America Pain Management Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 57: North America Pain Management Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 58: Europe Pain Management Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 59: Europe Pain Management Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 60: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 61: Europe Pain Management Therapeutics Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 62: Europe Pain Management Therapeutics Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 63: Europe Pain Management Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 64: Europe Pain Management Therapeutics Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 65: Europe Pain Management Therapeutics Market Value Share Analysis, By Pain Type, 2024 and 2035
Figure 66: Europe Pain Management Therapeutics Market Attractiveness Analysis, By Pain Type, 2025 to 2035
Figure 67: Europe Pain Management Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 68: Europe Pain Management Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 69: Europe Pain Management Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
Figure 70: Europe Pain Management Therapeutics Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 71: Europe Pain Management Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 72: Europe Pain Management Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 73: Asia Pacific Pain Management Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 74: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 75: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 76: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 77: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 78: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 79: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 80: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Pain Type, 2024 and 2035
Figure 81: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, By Pain Type, 2025 to 2035
Figure 82: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 83: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 84: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
Figure 85: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 86: Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 87: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 88: Latin America Pain Management Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 89: Latin America Pain Management Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 90: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 91: Latin America Pain Management Therapeutics Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 92: Latin America Pain Management Therapeutics Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 93: Latin America Pain Management Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 94: Latin America Pain Management Therapeutics Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 95: Latin America Pain Management Therapeutics Market Value Share Analysis, By Pain Type, 2024 and 2035
Figure 96: Latin America Pain Management Therapeutics Market Attractiveness Analysis, By Pain Type, 2025 to 2035
Figure 97: Latin America Pain Management Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 98: Latin America Pain Management Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 99: Latin America Pain Management Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
Figure 100: Latin America Pain Management Therapeutics Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 101: Latin America Pain Management Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 102: Latin America Pain Management Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 103: Middle East & Africa Pain Management Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 104: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 105: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 106: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 107: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 108: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 109: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 110: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Pain Type, 2024 and 2035
Figure 111: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, By Pain Type, 2025 to 2035
Figure 112: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 113: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 114: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
Figure 115: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 116: Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 117: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pain Management Therapeutics Market